Nanovibronix Inc
NASDAQ:NAOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nanovibronix Inc
Total Receivables
Nanovibronix Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nanovibronix Inc
NASDAQ:NAOV
|
Total Receivables
$115k
|
CAGR 3-Years
-21%
|
CAGR 5-Years
3%
|
CAGR 10-Years
28%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Total Receivables
$912.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Receivables
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$7.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
15%
|
|
Nanovibronix Inc
Glance View
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Elmsford, New York and currently employs 12 full-time employees. The company went IPO on 2015-04-24. The firm is focused on developing noninvasive biological response-activating devices utilizing its low intensity surface acoustic wave (SAW) technology, which targets biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products, which are in various stages of clinical and market development consist of UroShield, PainShield and WoundShield. Its PainShield family of products include PainShield MD, PainShield Plus and PainShield Relief. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. Its wholly owned subsidiary is NanoVibronix Ltd.
See Also
What is Nanovibronix Inc's Total Receivables?
Total Receivables
115k
USD
Based on the financial report for Sep 30, 2025, Nanovibronix Inc's Total Receivables amounts to 115k USD.
What is Nanovibronix Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
28%
Over the last year, the Total Receivables growth was -80%. The average annual Total Receivables growth rates for Nanovibronix Inc have been -21% over the past three years , 3% over the past five years , and 28% over the past ten years .
